This month, the U.S. Supreme Court will hear oral arguments in Wyeth v. Levine, a preemption case involving prescription medication labeling that some regard as the most significant business case this term. The case will greatly impact product liability practices and could invite new federal legislation. In addition, the growing popularity of aggregated proceedings in product cases has led the plaintiffs and defense bar to analyze the pros and cons of multidi...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In